Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor is in the midgut (small intestine or right colon) and cannot be removed by surgery.
- Your tumor is growing slowly (Ki-67 index 20% or less) and you have had clear progression in the last 3 years.
- You may have had treatment before, but not any type of radioactive drug therapy (PRRT).
- Your tumors must show strong uptake on a somatostatin receptor scan (hot spots).
- Your blood counts, kidney function, and liver function must be good enough (specific lab levels).
- You are able to care for yourself (Karnofsky score 70% or higher) and expect to live at least 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This study looks at whether a simple blood test (inflammation score) can predict how well the drug Lu-177 oxodotreotide (Lutathera) will work for people with midgut neuroendocrine tumors that have grown or spread. It may help doctors understand who benefits most from this treatment.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
Hear when a new Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.